Menlo Therapeutics Inc. (MNLO)
(Delayed Data from NSDQ)
$6.96 USD
-0.04 (-0.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.96 USD
-0.04 (-0.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Menlo Therapeutics Inc. (MNLO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.
Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.
Menlo Therapeutics Inc (MNLO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.
Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y
by Zacks Equity Research
Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.
ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.
Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y
by Zacks Equity Research
Blueprint Medicines (BPMC) betters loss estimates while revenues beat the mark in the first quarter. Higher collaboration revenues and a surge in product sales aid results.
Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.
Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.
Menlo Therapeutics Inc. (MNLO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).
Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.
Menlo (MNLO) in Focus: Stock Moves 9.9% Higher
by Zacks Equity Research
Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
by Zacks Equity Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Menlo Stock Plunges on Phase II Chronic Cough Study Failure
by Zacks Equity Research
Menlo Therapeutics' (MNLO) sole pipeline candidate, serlopitant, fails to meet endpoint in a phase II study in refractory chronic cough patients. Study to be terminated.